N-acetylcysteine (NAC) in Endometriosis: Oxidative Stress and Pelvic Pain

A clear review of how this glutathione precursor acts on oxidative stress, inflammation, and pain in endometriosis, and what current scientific evidence shows.

1. Endometriosis: oxidative stress, inflammation, and pain

If you live with endometriosis, adenomyosis, fibroids, or very painful periods, you know that pain and lesion progression do not depend solely on estrogens. There is a complex biological environment in which oxidative stress and chronic inflammation play a key role in maintaining symptoms and promoting ectopic tissue proliferation.

In women with endometriosis, increased oxidative stress has been described in the peritoneal fluid, with excess reactive oxygen species (ROS), which promotes tissue damage, persistent inflammation, angiogenesis, and cellular invasion. This inflammatory environment is sustained, among other pathways, by activation of routes such as NF-κB and by pro-inflammatory cytokines such as IL-6 or TNF-α.

These targets—oxidative stress, chronic inflammation, and tissue proliferation—are currently relevant in the pathophysiological approach to endometriosis.

2. What is N-acetylcysteine (NAC) and why is it relevant in endometriosis

N-acetylcysteine (NAC) is the acetylated form of the amino acid cysteine and is widely known in clinical and nutritional settings for its role in the body's antioxidant system.

NAC has been studied for its ability to:

• Act as a direct precursor of glutathione, the main intracellular antioxidant
  
  

• Scavenge free radicals directly, helping to reduce oxidative stress
  
  

• Modulate inflammatory pathways such as NF-κB, reducing pro-inflammatory cytokines
  
  

• Exert anti-proliferative and pro-apoptotic effects in various cellular models
  
  

This profile makes it a particularly interesting compound in conditions where high oxidative stress, chronic inflammation, and tissue proliferation coexist, as in endometriosis.

In EndoRestore™, NAC is used as part of a strategy aimed at reducing oxidative burden and modulating the inflammatory environment that supports lesion persistence.

3. Clinical evidence in pain and endometriotic lesions

Available clinical research suggests that NAC may play a relevant role as an adjunct in managing pain and lesion progression in women with endometriosis.

An Italian clinical trial showed that three months of NAC supplementation were associated with a reduction in endometrioma size and improvement in pain, with good tolerance and reduced need for surgical or pharmacological treatment (Porpora et al., 2013; Benaglia et al., 2019).

Other studies have also reported improvements in dysmenorrhea and pain scores, along with reduced use of analgesics (Sanaei et al., 2020; Anastasi et al., 2023).

These findings support the idea that reducing oxidative stress and modulating inflammation may translate into real clinical benefits for women with endometriosis.

4. Mechanistic evidence: oxidative stress, inflammation, and cell proliferation

From a pathophysiological perspective, NAC directly targets altered processes in endometriosis.

Excess ROS promotes angiogenesis, proliferation, and cellular invasion, while sustaining inflammation. By increasing glutathione availability and acting as a direct antioxidant, NAC helps reduce oxidative damage and limit this cascade of pro-inflammatory signals.

Additionally, modulation of pathways such as NF-κB and reduction of pro-inflammatory cytokines help create a microenvironment less favorable for the persistence and progression of endometriotic lesions.

Overall, these mechanisms align with key pathophysiological targets in endometriosis: less oxidative stress, reduced inflammation, and decreased proliferative signaling.

5. NAC within an integrative approach

Reviews on supplementation in endometriosis (Yalçın Bahat et al., 2022) position NAC among the compounds with the strongest scientific interest within a nutritional and complementary approach to the disease.

It is important to understand that NAC is not a standalone or replacement treatment, but a tool that can be integrated into a multimodal strategy: personalized nutrition, stress management, adapted exercise, and medical treatment when necessary.

6. Synergies in EndoRestore™

In EndoRestore™, NAC is combined with other compounds with complementary actions:

Alpha-lipoic acid (ALA)

ALA is a broad-spectrum antioxidant that acts in both aqueous and lipid environments and contributes to the regeneration of other endogenous antioxidants, helping to reduce cellular oxidative stress. Together, this synergy helps reduce the oxidative burden that drives chronic inflammation and progression of endometriotic lesions.

Bromelain

Bromelain is a proteolytic enzyme with anti-inflammatory properties that modulates inflammatory response and pain, commonly used as support in inflammatory and painful conditions. This synergy contributes to improved control of inflammation and pain associated with endometriosis within an integrative approach.

In the multicenter LEAP study (Lete et al., 2018), a formulation including NAC, ALA, bromelain, and zinc was evaluated over six months in women with endometriosis not receiving hormonal treatment, showing improvements in symptom-related variables throughout the cycle.

7. Clinical conclusion

N-acetylcysteine does not replace medical treatment for endometriosis. However, available evidence suggests it may be considered a nutritional support with a solid mechanistic basis and promising clinical data in modulating pain, oxidative stress, and lesion progression.

If you are looking for an ingredient that not only targets symptoms but also intervenes in processes such as oxidative stress, chronic inflammation, and cellular proliferation, NAC is an option with growing scientific support.

When integrated into a comprehensive strategy including nutrition, rest, and moderate exercise, and formulated in synergy with other compounds as in EndoRestore™, it may contribute to more sustained symptom improvement and better quality of life.

8. References

• Benaglia L, Bermejo A, Somigliana E, et al. Randomized controlled trial on N-acetylcysteine to reduce the size of ovarian endometriomas. Reprod Biomed Online. 2019;39(2):308–314.
  
  

• Porpora MG, Risalvato A, Piazze JJ, et al. A prospective cohort study on the efficacy of N-acetylcysteine in the treatment of endometriomas. Eur J Obstet Gynecol Reprod Biol. 2021;256:350–356.
  
  

• Sanaei M, Kianpour M, Azadbakht M, et al. Impact of N-acetylcysteine on oxidative stress and pain scores in women with endometriosis. J Obstet Gynaecol Res. 2020;46(10):1920–1926.
  
  

• Anastasi E, et al. Efficacy of N-Acetylcysteine in endometriosis-related pain, endometrioma size and fertility outcomes (prospective cohort). Int J Environ Res Public Health. 2023;20(6):4686.

• Yalçın Bahat P, Ayhan I, Üreyen Özdemir E, İnceboz Ü, Oral E. Dietary supplements for treatment of endometriosis: A review. Acta Biomed. 2022;93(1):e2022159. PMID: 35315418.